October 16, 2025
Jacob
(no address supplied)
Email: [FYI request #32373 email]
Tēnā koe Jacob,
I am writing in response to your OIA request of 24 September. You sought:
Any communications between RNZ and the pharmaceutical company Janssen also known and
as Johnson and Johnson within the last year.
A request of the RNZ newsroom, which includes our health reporter and producers for major news
programmes such as Morning Report and Checkpoint, has identified just the one email conversation,
which is included in this letter.
I am sorry we have no further information. If there is a specific story (online) or broadcast that you wish
me to check further, please identify it so I can conduct additional research.
You have a right to seek an investigation and review by the Ombudsman of the above outcome.
Information about how to make a complaint is available at
www.ombudsman.parliament.nz or
freephone 0800 802 602.
Nāku, nā
Andrew Holden
OIA officer
Radio New Zealand House Level 2 155 The Terrace PO BOX 123 Wellington 6140 New Zealand +64 4 474 1999 www.rnz.co.nz
Gabrielle
Gabrielle Adams
Senior Manager
Communications & Public Affairs, ANZ
J&J Innovative Medicine
[email address]
M: +61 458 878 587
https://innovativemedicine.jnj.com/australia/
Janssen-Cilag Pty Ltd
66 Waterloo Road
Macquarie Park, NSW 2113
Confidentiality Notice: This e-mail transmission is confidential and may be privileged information that is intended only for the
individual or entity named in the e-mail address. If you are not the intended recipient and believe you have received this e-mail
transmission in error, please reply to the sender, so that we can arrange for proper delivery, and then please delete the message
from your inbox. The unauthorised use, dissemination, distribution or reproduction of this e-mail, including attachments, is
prohibited and may be unlawful. Receipt by anyone other than the intended recipient(s) is not a waiver of any attorney/client or other
privilege. Thank you.
Adverse Event Reporting:
If your message concerns an ADVERSE EVENT or SPECIAL SITUATION, please report it within 24 hours (and no later than
Calendar Day three (3) in the event of public holiday) via Email at [email address]. If not possible, please call 1800 226
334 (from Australia) or 0800 800 806 (from New Zealand) during business hours.
Product Quality Complaint Reporting:
If your message relates to a PRODUCT QUALITY COMPLAINT please report it within 24 hours (and no later than Calendar Day
three (3) in the event of public holiday) via Email at [email address]. If not possible, please call 1800 226 334
(from Australia) or 0800 800 806 (from New Zealand) during business hours.
Medical Information Enquiry:
If your email relates to a MEDICAL INFORMATION ENQUIRY, please visit www.janssenpro.com.au for available resources and
services or email: [email address]. Alternatively please call 1800 226 334 (from Australia) or 0800 800 806 (from New
Zealand) during business hours.
From: Louisa Cleave <[email address]>
Sent: Monday, 22 September 2025 6:56 AM
To: Media [JACAU] <[email address]>
Subject: [EXTERNAL] Checkpoint, Radio New Zealand
Hello
Checkpoint has been running a series of interviews with myeloma patients about access to
daratumumab.
Blood cancer patients say govt breaking promise on life-saving drugs | RNZ News
'Medical migrant' seeks life in Australia | RNZ News
We were interested in whether someone from jnj would be available to come on the
programme this week to discuss this medication and how it’s accessed by Kiwis. Some of
the points we are interested in exploring are what is offered to patients wanting access to
daratumumab, your understanding of why Pharmac is not funding the drug and what
overtures are being made to get this onto the list of funded drugs for NZ blood cancer
patients.
If there is an opportunity to speak to a company representative please let me know.
Many thanks,
Louisa Cleave |
Senior Producer, Checkpoint
Radio New Zealand | Level 3 | 171 Hobson St
PO Box 2209 | Auckland | New Zealand 1040 www.radionz.co.nz
9 (2) (a)
|
Emails sent by Radio New Zealand Limited (RNZ) or any related entity, including any
attachments, may be confidential, protected by copyright and/or subject to privilege.
If you receive an email from RNZ in error, please inform the sender immediately,
delete it from your system and do not use, copy or disclose any of the information in
that email for any purpose. Emails to/from RNZ may undergo email filtering and virus
scanning, including by third party contractors. However, RNZ does not guarantee that
any email or any attachment is secure, error-free or free of viruses or other unwanted
or unexpected inclusions. The views expressed in any non-business email are not
necessarily the views of RNZ. www.rnz.co.nz
CAUTION: This email originated from outside of the organization. Do not click links or
open attachments unless you recognize the sender and know the content is safe.
